Skip to main content
SpringerLink
Log in

Left Ventricular Fibrosis in Patients with Aortic Stenosis

  • Chapter
  • First Online:
Surgical Management of Aortic Pathology

Abstract

Aortic valve stenosis is the commonest form of valvular heart disease in the Western world, currently affecting about 7% of the population over the age of 60, while 3% of people over the age of 75 have severe stenosis. With an aging population, its prevalence is expected to increase dramatically in the next few decades with major financial implications for global healthcare systems. Aortic stenosis is characterized by progressive valve narrowing that leads to a high-pressure load on the left ventricle (LV), triggering hypertrophy of cardiac myocytes, and increase in LV wall thickness and mass.

At present there is no effective medical therapy capable of altering disease progression so that the only treatment is aortic valve replacement (AVR), usually with either surgical or percutaneous techniques. Current international guidelines recommended AVR in patients with severe stenosis and evidence of LV decompensation (either on the basis of symptoms or a reduced ejection fraction). Following AVR patients demonstrate a variable degree of regression of the ventricular hypertrophy with favorable prognosis demonstrated in the cohort of patients with the highest level of regression. Myocardial fibrosis is often seen in patients before intervention, and its presence is associated with worse perioperative and long-term outcome. In this chapter we review the literature pertaining to the importance of myocardial fibrosis in patients with aortic stenosis and evaluate the mechanisms, detection, and clinical significance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220–5.

    Article  CAS  Google Scholar 

  2. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60:1854–63.

    Article  Google Scholar 

  3. Carabello B. The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. J Hear Valve Dis. 1995;S2:S132–8.

    Google Scholar 

  4. Yarbrough W, Mukherjee R, Ikonomidis J, Zile M, Spinale F. NIH public access. J Thorac Cardiovasc Surg. 2012;143:656–64.

    Article  Google Scholar 

  5. Dunning J, Gao H, Chambers J, Moat N, Murphy G, Pagano D, et al. Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use--an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg. 2011;142:776–82.

    Article  Google Scholar 

  6. Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S, Lange V, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120:577–84.

    Article  CAS  Google Scholar 

  7. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.

    Article  Google Scholar 

  8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;148:e1–132.

    Google Scholar 

  9. Grossman W, Paulus WJ. Myocardial stress and hypertrophy: a complex interface between biophysics and cardiac remodeling. J Clin Invest. 2013;123:3701–3.

    Article  CAS  Google Scholar 

  10. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470–9.

    Article  CAS  Google Scholar 

  11. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J. 2005;26:1790–6.

    Article  Google Scholar 

  12. Chin CW, Vassiliou V, Jenkins WS, Prasad SK, Newby DE, Dweck MR. Markers of left ventricular decompensation in aortic stenosis. Expert Rev Cardiovasc Ther. 2014;12:901–2.

    Article  CAS  Google Scholar 

  13. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour A, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:50.

    Article  Google Scholar 

  14. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, McGaughey D, et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation. 1992;86:1099–107.

    Article  CAS  Google Scholar 

  15. Villar AV, García R, Merino D, Llano M, Cobo M, Montalvo C, et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol. 2013;167:2875–81.

    Article  Google Scholar 

  16. Douglas PS, Otto CM, Mickel MC, Labovitz A, Reid CL, Davis KB. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. Br Heart J. 1995;73:548–54.

    Article  CAS  Google Scholar 

  17. Villari B, Campbell SE, Schneider J, Vassalli G, Chiariello M, Hess OM. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J. 1995;16:1410–9.

    Article  CAS  Google Scholar 

  18. Pagé A, Dumesnil JG, Clavel M-A, Chan KL, Teo KK, Tam JW, et al. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin). J Am Coll Cardiol. 2010;55:1867–74.

    Article  Google Scholar 

  19. Lund BP, Gohlke-Bärwolf C, Cramariuc D, Rossebø AB, Rieck AE, Gerdts E. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy). Am J Cardiol. 2010;105:1456–60.

    Article  Google Scholar 

  20. Rieck AE, Cramariuc D, Staal EM, Rossebø AB, Wachtell K, Gerdts E. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). J Hypertens. 2010;28:377–83.

    Article  CAS  Google Scholar 

  21. Villari B, Hess OM, Kaufmann P, Krogmann ON, Grimm J, Krayenbuehl HP. Effect of aortic valve stenosis (pressure overload) and regurgitation (volume overload) on left ventricular systolic and diastolic function. Am J Cardiol. 1992;69:927–34.

    Article  CAS  Google Scholar 

  22. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003;107:984–91.

    Article  Google Scholar 

  23. Gonzalez A, Lopez B, Ravassa S, Querejeta R, Larman M, Diez J, et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension. 2002;39:75–80.

    Article  CAS  Google Scholar 

  24. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system. Circulation. 1991;83:1849–65.

    Article  CAS  Google Scholar 

  25. Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Hear J Cardiovasc Imaging. 2015;16:834–41.

    Article  Google Scholar 

  26. Singh A, Ford I, Greenwood JP, Khan JN, Uddin A, Berry C, et al. Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations. BMJ Open. 2013;3:e004348.

    Article  Google Scholar 

  27. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–6.

    Article  CAS  Google Scholar 

  28. McCrohon JA, Moon JCC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–9.

    Article  CAS  Google Scholar 

  29. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461–74.

    Article  Google Scholar 

  30. Stuckey DJ, McSweeney SJ, Thin MZ, Habib J, Price AN, Fiedler LR, et al. T1 mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. Circ Cardiovasc Imaging. 2014;7:240–9.

    Article  Google Scholar 

  31. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35:657–64.

    Article  CAS  Google Scholar 

  32. Perk G, Tunick PA, Kronzon I. Non-Doppler two-dimensional strain imaging by echocardiography--from technical considerations to clinical applications. J Am Soc Echocardiogr. 2007;20:234–43.

    Article  Google Scholar 

  33. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277–313.

    Article  Google Scholar 

  34. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation. 1990;81:58–64.

    Article  CAS  Google Scholar 

  35. Shiozaki AA, Senra T, Arteaga E, Martinelli Filho M, Pita CG, Ávila LFR, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7:173–81.

    Article  Google Scholar 

  36. Bandula S, White SK, Flett AS, Lawrence D, Pugliese F, Ashworth MT, et al. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology. 2013;269:396–403.

    Article  Google Scholar 

  37. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res. 2006;312:651–8.

    Article  CAS  Google Scholar 

  38. Jenkins WSA, Chin C, Rudd JHF, Newby DE, Dweck MR. What can we learn about valvular heart disease from PET/CT? Futur Cardiol. 2013;9:657–67.

    Article  CAS  Google Scholar 

  39. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–9.

    Article  Google Scholar 

  40. Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010;56:278–87.

    Article  Google Scholar 

  41. Nazarian S. Is ventricular arrhythmia a possible mediator of the association between aortic stenosis-related midwall fibrosis and mortality? J Am Coll Cardiol. 2011;58:1280–2.

    Article  Google Scholar 

  42. Quarto C, Dweck MR, Murigu T, Joshi S, Melina G, Angeloni E, et al. Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg. 2012;15:45–50.

    Article  Google Scholar 

  43. Milano AD, Faggian G, Dodonov M, Golia G, Tomezzoli A, Bortolotti U, et al. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg. 2012;144:830–7.

    Article  Google Scholar 

  44. Barone-Rochette G, Piérard S, De Meester de Ravenstein C, Seldrum S, Melchior J, Maes F, et al. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol. 2014;64:144–54.

    Article  Google Scholar 

  45. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141–6.

    Article  Google Scholar 

  46. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44.

    Article  Google Scholar 

  47. Chin CWL, Shah ASV, McAllister DA, Joanna Cowell S, Alam S, Langrish JP, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J. 2014;35:2312–21.

    Article  CAS  Google Scholar 

  48. Vassiliou V, Heng EL, Sharma P, Nyktari E, Raphael CE, Chin CW, et al. Reproducibility of T1 mapping 11-heart beat MOLLI sequence. J Cardiovasc Magn Resonance. 2015;17:W26.

    Article  Google Scholar 

  49. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206–16.

    Article  Google Scholar 

  50. Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS, et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012;13:819–26.

    Article  Google Scholar 

  51. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–8.

    Article  CAS  Google Scholar 

  52. Baldenhofer G, Zhang K, Spethmann S, Laule M, Eilers B, Leonhardt F, et al. Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). Int J Cardiol. 2014;177:912–7.

    Article  Google Scholar 

  53. Breyley JG, Novak E, Wittenberg AM, Zajarias A, Maniar H, Damiano R, et al. Soluble St2 is associated with increased mortality and reclassifies risk in patients with severe aortic stenosis. J Am Coll Cardiol. 2014;63:A1920.

    Article  Google Scholar 

  54. Zachariah JP, Colan SD, Lang P, Triedman JK, Alexander ME, Walsh EP, et al. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail. 2012;5:462–6.

    Article  CAS  Google Scholar 

  55. Tanaka-Esposito C, Varahan S, Jeyaraj D, Lu Y, Stambler BS. Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. J Cardiovasc Electrophysiol. 2014;25:537–44.

    Article  Google Scholar 

  56. Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107–17.

    Article  CAS  Google Scholar 

  57. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015;3:59–67.

    Article  Google Scholar 

  58. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185:537–46.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology and NIHR Biomedical Research Unit, Royal Brompton Hospital, London, UK

    Vassilis S. Vassiliou, Tamir Malley & Sanjay K. Prasad

  2. National Heart and Lung Institute, Imperial College London, London, UK

    Vassilis S. Vassiliou & Sanjay K. Prasad

  3. British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

    Calvin W. L. Chin, David E. Newby & Marc R. Dweck

  4. Department of Cardiovascular Medicine, National Heart Center Singapore, Singapore, Singapore

    Calvin W. L. Chin

Authors
  1. Vassilis S. Vassiliou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Calvin W. L. Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamir Malley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David E. Newby
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marc R. Dweck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sanjay K. Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vassilis S. Vassiliou .

Editor information

Editors and Affiliations

  1. Fmr Royal Brompton Hospital, London, UK

    Olaf H. Stanger

  2. Royal Brompton Hospital, London, UK

    John R. Pepper

  3. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA

    Lars G. Svensson

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Austria, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Vassiliou, V.S., Chin, C.W.L., Malley, T., Newby, D.E., Dweck, M.R., Prasad, S.K. (2019). Left Ventricular Fibrosis in Patients with Aortic Stenosis. In: Stanger, O., Pepper, J., Svensson, L. (eds) Surgical Management of Aortic Pathology. Springer, Vienna. https://doi.org/10.1007/978-3-7091-4874-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-4874-7_8

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-4872-3

  • Online ISBN: 978-3-7091-4874-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation